Cognitive Impairment/Dementia/Alzheimer's Lesson Objectives
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
SCHIZOPHRENIA and OTHER PSYCHOTIC DISORDERS of EARLY ONSET Jean Starling & Isabelle Feijo
IACAPAP Textbook of Child and Adolescent Mental Health Chapter OTHER DISORDERS H.5 SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS OF EARLY ONSET Jean Starling & Isabelle Feijo Jean Starling FRANZCP, MPH Child and adolescent psychiatrist, Director, Walker Unit, Concord Centre for Mental Health, Sydney, and senior clinical lecturer, Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia Conflict of interest: none declared Isabelle Feijo FRANZCP Psychiatrist, Walker Unit, Concord Centre for Mental Health, Sydney, Australia and specialist in child and adolescent psychiatry and psychotherapy, Swiss Medical Association Conflict of interest: none declared Jackson Acknowledgement: thanks to Pollock; Polly Kwan who vetted the untitled. Cantonese websites This publication is intended for professionals training or practising in mental health and not for the general public. The opinions expressed are those of the authors and do not necessarily represent the views of the Editor or IACAPAP. This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws of their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all dosages and unwanted effects are mentioned. Organizations, publications and websites are cited or linked to illustrate issues or as a source of further information. This does not mean that authors, the Editor or IACAPAP endorse their content or recommendations, which should be critically assessed by the reader. -
“What About Bob?” an Analysis of Gendered Mental Illness in a Mainstream Film Comedy
“What About Bob?” An Analysis of Gendered Mental Illness in a Mainstream Film Comedy A Thesis Presented in partial fulfillment of the requirements for the degree of Master of Arts in the College of Graduate Studies of Northeast Ohio Medical University. Anna Plummer M.D. Medical Ethics and Humanities 2020 Thesis Committee: Dr. Julie Aultman (Advisor) Dr. Rachel Bracken Brian Harrell Copyright Anna Plummer 2020 ABSTRACT Mental illness has been a subject of fictional film since the early 20th century and continues to be a popular trope in mainstream movies. Portrayals of affected individuals in movies tend to be inaccurate and largely stigmatizing, negatively influencing public perception of mental illness. Recent research suggests that gender stereotypes and mental illness intersect, such that some mental illnesses are perceived as “masculine” and others as “feminine.” This notion may further stigmatize such disorders in individuals, as well as falsely inflate observed gender disparities in certain mental illnesses. Since gendered mental illness is a newly identified concept, little research has been performed exploring the way stereotypical gendered mental illness is depicted in mainstream film. This paper analyzes the movie What About Bob? to show that comedic film perpetuates stigma surrounding feminine mental illness in men and identifies the need for further study of gendered mental illness in movies to ascertain the effect such depictions have on the observed gender disparities in prevalence of certain mental disorders, as well as offers a proposal for coursework for film and medical students. i ACKNOWLEDGMENTS This paper would not have been possible without Dr. Aultman, whose teaching inspired me to pursue further education in Medical Ethics and Humanities, and whose guidance has been invaluable not only for this project, but also for addressing ethical issues in the clinic. -
Bipolar Disorder in ADULTS the Disorder, Its Treatment and Prevention
Bipolar lidelse hos voksne, engelsk Information about BIPOLAR DISORDER IN ADULTS The disorder, its treatment and prevention Psykiatri og Social psykinfomidt.dk CONTENTS 03 What is bipolar disorder? 04 What causes bipolar disorder? 06 What are the symptoms of bipolar disorder? 09 How is bipolar disorder diagnosed? 10 Different progressions and modes of expression 11 How can bipolar disorder be treated and prevented? 14 What can you do to help yourself if you have bipolar disorder? 16 What can your loved ones do? Bipolar affective disorder (the term we will use in this publication is “bipolar disorder”) is a serious mental disorder. When a person has bipolar disorder, knowledge of the illness is important. The more you know, the better you can handle and prevent the illness and its consequences. This brochure describes the illness as well as options for its treatment and prevention. It is mainly intended for people being treated for bipolar disorder by the psychiatric service in Region Midtjylland. We hope this brochure will help you and your loved ones to learn more about the diagnosis of bipolar disorder. Kind regards The psychiatric service in Region Midtjylland Tingvej 15, 8800 Viborg Tel.: 7841 0000 Bipolar disorder in adults WHAT IS BIPOLAR DISORDER? Bipolar disorder is a mental illness lot in terms of reducing the progression characterised by episodes of mania, of symptoms and decreasing the hypomania (a mild form of mania), psychological and social costs to the depression and/or mixed state (a state individual and the family. where manic and depressive symptoms coexist or occur in rapid succession). -
White Matter Abnormalities in Adults with Bipolar Disorder Type-II
www.nature.com/scientificreports OPEN White matter abnormalities in adults with bipolar disorder type‑II and unipolar depression Anna Manelis1*, Adriane Soehner1, Yaroslav O. Halchenko2, Skye Satz1, Rachel Ragozzino1, Mora Lucero1, Holly A. Swartz1, Mary L. Phillips1 & Amelia Versace1 Discerning distinct neurobiological characteristics of related mood disorders such as bipolar disorder type‑II (BD‑II) and unipolar depression (UD) is challenging due to overlapping symptoms and patterns of disruption in brain regions. More than 60% of individuals with UD experience subthreshold hypomanic symptoms such as elevated mood, irritability, and increased activity. Previous studies linked bipolar disorder to widespread white matter abnormalities. However, no published work has compared white matter microstructure in individuals with BD‑II vs. UD vs. healthy controls (HC), or examined the relationship between spectrum (dimensional) measures of hypomania and white matter microstructure across those individuals. This study aimed to examine fractional anisotropy (FA), radial difusivity (RD), axial difusivity (AD), and mean difusivity (MD) across BD‑II, UD, and HC groups in the white matter tracts identifed by the XTRACT tool in FSL. Individuals with BD‑II (n = 18), UD (n = 23), and HC (n = 24) underwent Difusion Weighted Imaging. The categorical approach revealed decreased FA and increased RD in BD‑II and UD vs. HC across multiple tracts. While BD‑II had signifcantly lower FA and higher RD values than UD in the anterior part of the left arcuate fasciculus, UD had signifcantly lower FA and higher RD values than BD‑II in the area of intersections between the right arcuate, inferior fronto‑occipital and uncinate fasciculi and forceps minor. -
Antipsychotic Medication Reduction
So tonight we'll be discussing antipsychotic medication reduction. I'm happy to share some of my experiences with this challenging initiative and in nursing homes. I have no financial affiliations to disclose. And for our objectives and our agenda today, we're going to assess and evaluate appropriate antipsychotic medication use in nursing home residents, and apply strategies toward behavior management and antipsychotic medication reduction. The first part of the program we'll look at current trends and rates of antipsychotic medication use. We'll discuss the CMS initiative and latest policy issues. And then we'll look at a couple case studies. So first off, this first graph goes over the national progress in reducing the inappropriate use of antipsychotic medications in nursing homes. The taller red bar gives us the 2011 baseline number of 23.9%. That's a dotted red line indicates the start of the 2012 CMS initiative. That's the National Partnership to Improve Dementia Care in Nursing Homes. The latest information all the way down at the end is from the third quarter of 2018, which shows that nationally we have a 14.6% use rate. Overall, this looks like a reduction of nearly 40% since the initiative began. Overall though, I think this is great progress. Why should we be concerned with antipsychotic medications at all in this population? I have to say, that when I first exited my training from psychiatry and geriatric psychiatry, the black box warning had not yet come out. And it hit me that most of all the training that I learned was getting reversed when I entered the care setting. -
Included Diagnosis List
Press TAB to Diagnosis Diagnosis Description Code F20.0 Paranoid Schizophrenia F20.1 Disorganized Schizophrenia F20.2 Catatonic Schizophrenia F20.3 Undifferentiated Schizophrenia F20.5 Residual Schizophrenia F20.81 Schizophreniform Disorder F20.89 Other Schizophrenia F20.9 Schizophrenia, Unspecified F21 Schizotypal Disorder F22 Delusional Disorder F23 Brief Psychotic Disorder F24 Shared Psychotic Disorder F25.0 Schizoaffective Disorder, Bipolar Type F25.1 Schizoaffective Disorder, Depressive Type F25.8 Other Schizoaffective Disorders F25.9 Schizoaffective Disorder, Unspecified F28 Other Psychotic Disorder Not Due to a Substance or Known Physiological Condition F29 Unspecified Psychosis Not Due to a Substance or Known Physiological Condition F30.10 Manic Episode Without Psychotic Symptoms, Unspecified F30.11 Manic Episode Without Psychotic Symptoms, Mild F30.12 Manic Episode Without Psychotic Symptoms, Moderate F30.13 Manic Episode, Severe, Without Psychotic Symptoms F30.2 Manic Episode, Severe, With Psychotic Symptoms F30.3 Manic Episode in Partial Remission F30.4 Manic Episode in Full Remission F30.8 Other Manic Episodes F30.9 Manic Episode, Unspecified F31.0 Bipolar Disorder, Current Episode Hypomanic F31.10 Bipolar Disorder, Current Episode Manic, Without Psychotic features, Unspecified F31.11 Bipolar Disorder, Current Episode Manic, Without Psychotic Features, Mild F31.12 Bipolar Disorder, Current Episode Manic, Without Psychotic Features, Moderate F31.13 Bipolar Disorder, Current Episode Manic, Without Psychotic Features, Severe F31.2 -
The Clinical Presentation of Psychotic Disorders Bob Boland MD Slide 1
The Clinical Presentation of Psychotic Disorders Bob Boland MD Slide 1 Psychotic Disorders Slide 2 As with all the disorders, it is preferable to pick Archetype one “archetypal” disorder for the category of • Schizophrenia disorder, understand it well, and then know the others as they compare. For the psychotic disorders, the diagnosis we will concentrate on will be Schizophrenia. Slide 3 A good way to organize discussions of Phenomenology phenomenology is by using the same structure • The mental status exam as the mental status examination. – Appearance –Mood – Thought – Cognition – Judgment and Insight Clinical Presentation of Psychotic Disorders. Slide 4 Motor disturbances include disorders of Appearance mobility, activity and volition. Catatonic – Motor disturbances • Catatonia stupor is a state in which patients are •Stereotypy • Mannerisms immobile, mute, yet conscious. They exhibit – Behavioral problems •Hygiene waxy flexibility, or assumption of bizarre • Social functioning – “Soft signs” postures as most dramatic example. Catatonic excitement is uncontrolled and aimless motor activity. It is important to differentiate from substance-induced movement disorders, such as extrapyramidal symptoms and tardive dyskinesia. Slide 5 Disorders of behavior may involve Appearance deterioration of social functioning-- social • Behavioral Problems • Social functioning withdrawal, self neglect, neglect of • Other – Ex. Neuro soft signs environment (deterioration of housing, etc.), or socially inappropriate behaviors (talking to themselves in -
Psychotropic Medication Concerns When Treating Individuals with Developmental Disabilities
Tuesday, 2:30 – 4:00, C2 Psychotropic Medication Concerns when Treating Individuals with Developmental Disabilities Richard Berchou 248-613-6716 [email protected] Objective: Identify effective methods for the practical application of concepts related to improving the delivery of services for persons with developmental disabilities Notes: Medication Assistance On-Line Resources OBTAINING MEDICATION: • Needy Meds o Needymeds.com • Partnership for Prescriptions Assistance o Pparx.org • Patient Assistance Program Center o Rxassist.org • Insurance coverage & Prior authorization forms for most drug plans o Covermymeds.com REMINDERS TO TAKE MEDICATION: • Medication reminder by Email, Phone call, or Text message o Sugaredspoon.com ANSWER MOST QUESTIONS ABOUT MEDICATIONS: • Univ. of Michigan/West Virginia Schools of Pharmacy o Justaskblue.com • Interactions between medications, over-the-counter (OTC) products and some foods; also has a pictorial Pill Identifier: May input an entire list of medications o Drugs.com OTHER TRUSTED SITES: • Patient friendly information about disease and diagnoses o Mayoclinic.com, familydoctor.org • Package inserts, boxed warnings, “Dear Doctor” letters (can sign up to receive e- mail alerts) o Dailymed.nlm.nih.gov • Communications about drug safety o www.Fda.gov/cder/drug/drugsafety/drugindex.htm • Purchasing medications on-line o Pharnacychecker.com Updated 2013 Psychotropic Medication for Persons with Developmental Disabilities April 23, 2013 Richard Berchou, Pharm. D. Assoc. Clinical Prof., Dept. Psychiatry & Behavioral -
Psychiatric Assessment of Severe Presentations in Autism Spectrum Disorders and Intellectual Disability
Psychiatric Assessment of Severe Presentations in Autism Spectrum Disorders and Intellectual Disability a,b, b Bryan H. King, MD *, Nina de Lacy, MD , c,d,e Matthew Siegel, MD KEYWORDS Autism Intellectual disability Self-injury Aggression Hyperactivity Psychiatric evaluation KEY POINTS Psychiatric illnesses are common in autism spectrum disorder (ASD)/intellectual disability (ID). Externalizing behaviors are common presenting symptoms but are etiologically nonspecific. Genetic conditions associated with ASD/ID may inform medical surveillance as well as potential therapeutics. Co-occurring medical conditions are common in ASD/ID and may contribute to symptom presentation. Environmental factors, for example, change in caregiver or experience of trauma, may be particularly significant in the setting of ASD/ID. INTRODUCTION Decades ago, Sovner and Hurley1 somewhat rhetorically debated whether individ- uals with ID experience affective illness. Although the answer then as now is an un- equivocal yes, uncertainty does remain as to how the presentation of psychiatric Disclosure Statement: B.H. King has received research funding and has served as a consultant for Seaside Therapeutics and Roche. Drs N. de Lacy and M. Siegel report no financial disclosures. a Department of Psychiatry and Behavioral Medicine, Seattle Children’s Autism Center, Seattle Children’s Hospital, Seattle, WA, USA; b Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; c Developmental Disorders Program, Spring Harbor Hospital, ME, USA; d Tufts University School of Medicine, Boston, MA, USA; e Maine Medical Center Research Institute, ME, USA * Corresponding author. E-mail address: [email protected] Child Adolesc Psychiatric Clin N Am 23 (2014) 1–14 http://dx.doi.org/10.1016/j.chc.2013.07.001 childpsych.theclinics.com 1056-4993/14/$ – see front matter Ó 2014 Elsevier Inc. -
A Call for Research on the Development of MDD with Psychotic Features Christopher P
A Call for Research on the Development of MDD with Psychotic Features Christopher P. M. Courtney Faculty Advisor: Dr. Meredith Montgomery, LPCC-S Part 1: Background Part 2: Literature Review Part 3: Psychosocial Development Neurochemistry Erikson’s Psychosocial Development • The Dopamine Hypothesis states that • Considering Erikson's psychosocial stage theory17, MDD symptoms of psychosis (particularly as w/ psychotic features onset seems to increase with ego seen in schizophrenia, which MDD with development between adolescence & later life18. psychotic features can mimic or even • When the fidelity of adolescence falls to the converse of develop into) can be attributed to a identity, that is, identity confusion19, it throws a normative disturbed dopaminergic signal transduction8 experience into a storm of insecurity, which easily can • Bupropion, better known as Wellbutrin, is start and lead to a core disturbance. Intro and Occurrence Stats currently one of the more prescribed anti-depressants, and according to • Young adulthood then begins as a search for intimacy, as In recent years, Major Depressive Disorder (MDD) is Moreira9 extremely effective in the regulation of clinical depression; those at this stage begin to turn outward in an attempt to becoming more normalized considering medication for it specifically, as it inhibits the reuptake of dopamine through the dopamine share their newfound identity. The antithesis of isolation appears in commercials and other media on a regular basis. and norepinephrine transporters10. It must be noted that this is an enters, as those who failed to reconcile the preceding Psychotic symptoms, an often-misunderstood specifier for unusual function for an anti-depressant, although in this case it allows it to identity conflict feel either that they are psychologically this disorder, are occurring more frequently while being work in tandem with anti-psychotics such as Aripiprazole11. -
Formal Thought Disorder in First-Episode Psychosis
Available online at www.sciencedirect.com ScienceDirect Comprehensive Psychiatry 70 (2016) 209–215 www.elsevier.com/locate/comppsych Formal thought disorder in first-episode psychosis Ahmet Ayera, Berna Yalınçetinb, Esra Aydınlıb, Şilay Sevilmişb, Halis Ulaşc, Tolga Binbayc, ⁎ Berna Binnur Akdedeb,c, Köksal Alptekinb,c, aManisa Psychiatric Hospital, Manisa, Turkey bDepartment of Neuroscience, Dokuz Eylul University, Izmir, Turkey cDepartment of Psychiatry, Medical School of Dokuz Eylul University, Izmir, Turkey Abstract Formal thought disorder (FTD) is one of the fundamental symptom clusters of schizophrenia and it was found to be the strongest predictor determining conversion from first-episode acute transient psychotic disorder to schizophrenia. Our goal in the present study was to compare a first-episode psychosis (FEP) sample to a healthy control group in relation to subtypes of FTD. Fifty six patients aged between 15 and 45 years with FEP and forty five control subjects were included in the study. All the patients were under medication for less than six weeks or drug-naive. FTD was assessed using the Thought and Language Index (TLI), which is composed of impoverishment of thought and disorganization of thought subscales. FEP patients showed significantly higher scores on the items of poverty of speech, weakening of goal, perseveration, looseness, peculiar word use, peculiar sentence construction and peculiar logic compared to controls. Poverty of speech, perseveration and peculiar word use were the significant factors differentiating FEP patients from controls when controlling for years of education, family history of psychosis and drug abuse. © 2016 Elsevier Inc. All rights reserved. 1. Introduction Negative FTD, identified with poverty of speech and poverty in content of speech, remains stable over the course of Formal thought disorder (FTD) is one of the fundamental schizophrenia [7]. -
CHAPTER 6 Sleep and Stroke G.J
CHAPTER 6 Sleep and Stroke G.J. Meskill*, C. Guilleminault** *Comprehensive Sleep Medicine Associates, Houston, TX, USA **The Stanford Center for Sleep Sciences and Medicine, Redwood City, CA, USA OUTLINE Introduction 115 Stroke, Parasomnias, and Sleep- Related Movement Disorders 120 Sleep Apnea is a Risk Factor for Stroke 115 Diagnosis 120 Pathophysiology 116 Treatment 122 Stroke Increases the Risk of Sleep Apnea 118 Conclusions 123 Stroke and the Sleep–Wake Cycle 118 References 124 INTRODUCTION Stroke, defined as a focal neurological deficit of acute onset and vascular origin, is the sec- ond leading cause of death worldwide and is a major source of physical, psychological, and monetary hardship. There are more than 15 million cases worldwide annually, and 795,000 in the United States alone. In total, 137,000 stroke patients will die from stroke complications, and more than 50% will have physical and mental impairment.1 Factoring healthcare services, medications, and productivity loss, strokes cost the United States $34 billion annually.2 SLEEP APNEA IS A RISK FACTOR FOR STROKE Obstructive sleep apnea (OSA) is characterized by recurrent episodes of partial or complete interruption in breathing during sleep due to increased upper airway resistance. OSA has been identified as an independent risk factor for several cardiovascular and cerebrovascular Sleep and Neurologic Disease. http://dx.doi.org/10.1016/B978-0-12-804074-4.00006-6 Copyright © 2017 Elsevier Inc. All rights reserved. 115 116 6. SLEEP AND STROKE morbidities, including hypertension, ischemic heart disease, heart failure, atrial fibrillation, and hypertrophic cardiomyopathy.3–6 The incidence of OSA varies due to significant differ- ences in the sensitivity of testing sites, testing modalities (e.g., in-laboratory polysomnog- raphy vs.